Hibiscus Bioventures

Hibiscus Bioventures is a biotechnology startup studio based in Rockville, Maryland. Founded in 2019, it builds and invests in companies operating in the biotechnology and pharmaceutical sectors.

Cai Yaoting

Partner

3 past transactions

AsclepiX Therapeutics

Series A in 2023
AsclepiX Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for retinal diseases and certain cancers. The company specializes in designing short biomimetic peptides that target angiogenesis and lymphangiogenesis, utilizing advanced bioinformatics and systems biology approaches. Its lead product candidates, including AXT107, AXT201, AXT301, and AXT501, are aimed at addressing conditions such as diabetic macular edema, age-related macular degeneration, and macular edema from retinal vein occlusion, all of which are significant causes of blindness in the western world. Additionally, AXT201, AXT301, and AXT501 are in early development stages for treating various solid tumors. AsclepiX Therapeutics employs cutting-edge biomaterials and drug delivery systems, including biodegradable nano and microparticles, to enhance the therapeutic efficacy of its peptide-based treatments. Incorporated in 2011 and headquartered in Baltimore, Maryland, the company is leveraging its platform technology to advance solutions in both ophthalmology and oncology.

Leto Laboratories

Series C in 2022
Leto Laboratories develops and researches advanced protein re‑engineering platforms to create novel therapeutic proteins. The company focuses on high‑throughput protein re‑screening, purification, fixed‑point coupling design, and formulation development to accelerate the creation of effective protein‑based drugs for cancer and rare disease patients.

Cellevolve Bio

Seed Round in 2021
Cellevolve Bio is a development and commercialization company specializing in cell therapies aimed at neglected diseases. The company collaborates with innovators to transition early-stage clinical therapies into commercially available treatments, particularly for pediatric and rare diseases. By advancing these therapies into clinical development, Cellevolve aims to significantly enhance patient outcomes and provide expertise in cell therapy and clinical care.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.